These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12489027)

  • 1. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.
    McCarthy HO; Yakkundi A; McErlane V; Hughes CM; Keilty G; Murray M; Patterson LH; Hirst DG; McKeown SR; Robson T
    Cancer Gene Ther; 2003 Jan; 10(1):40-8. PubMed ID: 12489027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.
    McErlane V; Yakkundi A; McCarthy HO; Hughes CM; Patterson LH; Hirst DG; Robson T; McKeown SR
    J Gene Med; 2005 Jul; 7(7):851-9. PubMed ID: 15712360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.
    Yakkundi A; McErlane V; Murray M; McCarthy HO; Ward C; Hughes CM; Patterson LH; Hirst DG; McKeown SR; Robson T
    Cancer Gene Ther; 2006 Jun; 13(6):598-605. PubMed ID: 16410820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug.
    Raleigh SM; Wanogho E; Burke MD; Patterson LH
    Xenobiotica; 1999 Nov; 29(11):1115-22. PubMed ID: 10598746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy.
    Patterson LH
    Drug Metab Rev; 2002 Aug; 34(3):581-92. PubMed ID: 12214668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells.
    Hejmadi MV; McKeown SR; Friery OP; McIntyre IA; Patterson LH; Hirst DG
    Br J Cancer; 1996 Feb; 73(4):499-505. PubMed ID: 8595165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
    Chen L; Waxman DJ
    Curr Pharm Des; 2002; 8(15):1405-16. PubMed ID: 12052216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.
    Lalani AS; Alters SE; Wong A; Albertella MR; Cleland JL; Henner WD
    Clin Cancer Res; 2007 Apr; 13(7):2216-25. PubMed ID: 17404106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts.
    Williams KJ; Albertella MR; Fitzpatrick B; Loadman PM; Shnyder SD; Chinje EC; Telfer BA; Dunk CR; Harris PA; Stratford IJ
    Mol Cancer Ther; 2009 Dec; 8(12):3266-75. PubMed ID: 19996276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug.
    Raleigh SM; Wanogho E; Burke MD; McKeown SR; Patterson LH
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):763-7. PubMed ID: 9845092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.
    Gallagher R; Hughes CM; Murray MM; Friery OP; Patterson LH; Hirst DG; McKeown SR
    Br J Cancer; 2001 Aug; 85(4):625-9. PubMed ID: 11506506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study.
    Albertella MR; Loadman PM; Jones PH; Phillips RM; Rampling R; Burnet N; Alcock C; Anthoney A; Vjaters E; Dunk CR; Harris PA; Wong A; Lalani AS; Twelves CJ
    Clin Cancer Res; 2008 Feb; 14(4):1096-104. PubMed ID: 18281542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase.
    Mehibel M; Singh S; Cowen RL; Williams KJ; Stratford IJ
    Oncol Rep; 2016 Apr; 35(4):1925-32. PubMed ID: 26782976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol.
    Rainov NG; Dobberstein KU; Sena-Esteves M; Herrlinger U; Kramm CM; Philpot RM; Hilton J; Chiocca EA; Breakefield XO
    Hum Gene Ther; 1998 Jun; 9(9):1261-73. PubMed ID: 9650611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N).
    Mehibel M; Singh S; Chinje EC; Cowen RL; Stratford IJ
    Mol Cancer Ther; 2009 May; 8(5):1261-9. PubMed ID: 19435866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of AQ4N and its reduction product on radiation-mediated DNA strand breakage.
    Ali MM; Symons MC; Taiwo FA; Patterson LH
    Chem Biol Interact; 1999 Nov; 123(1):1-10. PubMed ID: 10597898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
    Jounaidi Y; Waxman DJ
    Cancer Res; 2000 Jul; 60(14):3761-9. PubMed ID: 10919648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AQ4N: a new approach to hypoxia-activated cancer chemotherapy.
    Patterson LH; McKeown SR
    Br J Cancer; 2000 Dec; 83(12):1589-93. PubMed ID: 11104551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.